REFERENCE LIST

1. Guidelines for the assessment and management of chronic obstructive pulmonary disease. Canadian Thoracic Society Workshop Group. CMAJ 1992; 147:420-28.
   
   
2. Hurd SS. International efforts directed at attacking the problem of COPD. Chest 2000; 117(5 Suppl 2):336S-38S.
   
   
3. WHO. Chronic Obstructive Pulmonary Disease. http://tobacco.who.int/en/health/copd.html. 2000.
   
   
4. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. Stamford, Connecticut: Appleton & Lange, 1999.
   
   
5. Canadian Respiratory Review Panel. Guidelines for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). 1-46. 1998. Toronto, Optimal Therapy Initiative/MUMS.
   
   
6. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343:269-80.
   
   
7. Celli BR, Snider GL, Heffner J, Tiep B, Ziment I, Make B et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152(5 (part 2)):S77-120.
   
   
8. Voelkel NF. Raising awareness of COPD in primary care. Chest 2000; 117(5 Suppl 2):372S-75S.
   
   
9. Harrison's Principles of Internal Medicine. 13th ed. New York: McGraw-Hill Inc., 1994.
   
   
10. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000; 117(2 Suppl):10S-4S.
    
    
11. Calverley P, Bellamy D. The challenge of providing better care for patients with chronic obstructive pulmonary disease: the poor relation of airways obstruction? Thorax 2000; 55:78-82.
    
    
12. O'Hagan J. Prevention of Chronic Obstructive Pulmonary Disease: A Challenge for the Health Professions. NZMedJ 1996; 109:1-3.
    
    
13. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52 Suppl 5:S1-28.
    
    
14. Therapeutic Choices. 3rd ed. Ottawa: Canadian Pharmacists Association, 2000.
    
    
15. Celli BR. The importance of spirometry in COPD and asthma: effect on approach to management. Chest 2000; 117(2 Suppl):15S-9S.
    
    
16. Ford GT, Borycki E. Managing chronic obstructive pulmonary disease. Can J CME 2000; September:133-51.
    
    
17. Canadian Immunization Guide. 5th ed. Canadian Medical Association, 1998.
    
    
18. Barnes PJ, Buist AS. The role of Anticholinergics in Chronic Obstructive Pulmonary Disease and Chronic Asthma. 1st ed. Cheshire: Gardiner-Caldwell Communications Ltd, 1997.
    
    
19. Compendium of Pharmaceuticals and Specialties (CPS). 35th ed. Ottawa: Canadian Pharmacists Association, 2000.
    
    
20. Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: A retrospective analysis of data from seven clinical trials. Chest 1996; 110:62-70.
    
    
21. Lotvall J. Pharmacology of bronchodilators used in the treatment of COPD. Respir Med 2000; 94 Suppl E:S6-10.
    
    
22. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999; 159:156-60.
    
    
23. Cook D, Guyatt G, Wong E, Goldstein R, Bedard M, Austin P et al. Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:85-90.
    
    
24. Crockett AJ, Moss JR, Cranston JM, Alpers JH. Domicilary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2000;(2):CD001744.
    
    
25. Appleton S, Smith B, Veale A, Bara A. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2000;(2):CD001104.
    
    
26. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115:957-65.
    
    
27. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15:878-85.
    
    
28. van Schayck CP. Do long-acting beta2-adrenergic agonists deserve a different place in guidelines for the treatment of asthma and COPD? Eur Respir J 2000; 15:631-34.
    
    
29. Cazzola M, Di Lorenzo G, Di Perna F, Calderaro F, Testi R, Centanni S. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest 2000; 118:1576-81.
    
    
30. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 1991; 114:216-23.
    
    
31. Postma DS, Kerstjens HA. Are inhaled glucocorticosteroids effective in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 1999; 160(5 Pt 2):S66-S71.
    
    
32. The Lung Health Study Research Group. Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary Disease. N Engl J Med 2000; 343:1902-09.
    
    
33. Pauwels RA, Lofdahl CG, Laitinen LA. Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease who Continue Smoking. N Engl J Med 1999; 340:1948-53.
    
    
34. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomized controlled trial. Lancet 1999; 353:1819-23.
    
    
35. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-303.
    
    
36. Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 1999; 93:161-66.
    
    
37. Lofdahl CG, Postma DS, Laitinen LA, Ohlsson SV, Pauwels RA, Pride NB. The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respir Med 1998; 92:467-72.
    
    
38. Pauwels RA, Lofdahl CG, Pride NB, Postma DS, Laitinen LA, Ohlsson SV. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. Eur Respir J 1992; 5:1254-61.
    
    
39. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117(5 Suppl 2):398S-401S.
    
    
40. Wood-Baker R, Walters EH. Corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2000;(2):CD001288.
    
    
41. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340:1941-47.
    
    
42. Davis L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354:456-60.
    
    
43. Wedzicha JA. Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease. Thorax 2000; 55 Suppl 1:S23-7.
    
    
44. Balter MS. Recommendations on the management of chronic bronchitis: A practical guide for Canadian physicians. CMAJ 1994; 151(10 Suppl):1-23.
    
    
45. Gross NJ. Chronic obstructive pulmonary disease. Current concepts and therapeutic approaches. Chest 1990; 97(2 Suppl):19S-23S.
    
    
46. Difficult asthma. 1st ed. 1999.
    
    
47. Sorkness RL, Calhoun WJ, Busse WW. Neural control of the airways and cholinergic mechanisms. In: Weiss EB, Stein M, editors. Bronchial Asthma: Mechanisms and Therapeutics. Boston: Little, Brown, 2 A.D.: 217.
    
    
48. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary diseases, a combination of ipratropium bromide and albuterol is more effective than either agent alone: An 85-day multicenter trial. Chest 1994; 105:1411-19.
    
    
49. Applied Therapeutics: The Clinical Use of Drugs. 6th ed. Vancouver: Applied Therapeutics Inc., 1995.
    
    
50. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease. Br Med J 2000; 320:1297-1303.
    
    
51. Wilson DO, Rogers RM, Wright EC. Body weight in chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 139:1435-38.
    
    
52. Boulet LP, Becker A, Berube D, Beveridge R, Ernst P. Canadian asthma consensus report, 1999. CMAJ 1999; 161(11 Suppl):S1-S62.
    
    
53. Lacy CF, Armstrong LL, Goldman MP, Lange P. Drug Information Handbook. 7th ed. Cleveland: Lexi-comp, 1999.
    
    
54. Stedman's Medical Dictionary. 26th ed. Baltimore: Williams & Wilkins, 1995.
    
    
55. Hvizdos KM, Goa KL. Tiotropium Bromide. Drugs 2002; 62:1195-203.
    
    
56. Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8:1506-13.
    
    
57. Spiriva Product Monograph, 2002. Boehringer Ingelheim (Canada).
    
    
58. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47-55.
    
    
59. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1136-42.
    
    
60. Vincken W, Van Noord JA, Greefhorst APM, Bantje TA, Kesten S, Korducki L et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002; 19:209-216.